Australia's most trusted
source of pharma news
Posted 27 June 2025 AM
Eli Lilly is touting the success of an antibody in ensuring weight loss from a GLP-1 is from fat rather than muscle, but there's just one quirk - the trial used rival, Novo Nordisk's drug in the combo.
Results presented at the American Diabetes Association annual conference of the placebo-controlled Phase IIb BELIEVE study which enrolled more than 500 patients who were given subcutaneous Wegovy weekly and intravenous monoclonal antibody bimagrumab at weeks 4, 16, 28, and 40 showed that the combination reduced weight by 22.1 per cent at 72 weeks.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.